APA (7th ed.) Citation

Tinker, A. V., Altman, A. D., Bernardini, M. Q., Ghatage, P., Gien, L. T., Provencher, D., . . . Oza, A. M. (2022). A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers. Current Oncology, 29(6), 4354. https://doi.org/10.3390/curroncol29060348

Chicago Style (17th ed.) Citation

Tinker, Anna V., Alon D. Altman, Marcus Q. Bernardini, Prafull Ghatage, Lilian T. Gien, Diane Provencher, Shannon Salvador, Sarah Doucette, and Amit M. Oza. "A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers." Current Oncology 29, no. 6 (2022): 4354. https://doi.org/10.3390/curroncol29060348.

MLA (9th ed.) Citation

Tinker, Anna V., et al. "A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers." Current Oncology, vol. 29, no. 6, 2022, p. 4354, https://doi.org/10.3390/curroncol29060348.